Protara Therapeutics
TARA
29 hedge funds and large institutions have $16.9M invested in Protara Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
15% more capital invested
Capital invested by funds: $14.6M → $16.9M (+$2.25M)
0.05% more ownership
Funds ownership: 48.61% → 48.66% (+0.05%)
6% less funds holding
Funds holding: 31 → 29 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$193K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$104K |
| 3 |
LPL Financial
San Diego,
California
|
+$33.1K |
| 4 |
BlackRock
New York
|
+$2.42K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$123K |
| 2 |
Two Sigma Advisers
New York
|
-$51.6K |
| 3 |
Two Sigma Investments
New York
|
-$34.4K |
| 4 |
Renaissance Technologies
New York
|
-$26.7K |
| 5 |
Millennium Management
New York
|
-$10.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $3.04K | -$4.39K | -1,329 | -58% |
|
27
Wells Fargo
San Francisco,
California
| $1.75K | +$3 | +1 | +0.2% |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $313 | – | – | – |
|
29
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$332 | -124 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$58 | -22 | Closed |
|
TARA Hedge Fund Activity: Q1 2023 in Review
29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2023, worth a combined $16.9M — up 15% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TARA and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $193K. The largest seller was OrbiMed, cutting an estimated $123K.
- 29 institutional investors held Protara Therapeutics (TARA) as of Q1 2023, down from 31 in Q4 2022.
- Funds reported $16.9M of Protara Therapeutics stock for Q1 2023, up 15% quarter-over-quarter.
- 1 fund opened new Protara Therapeutics positions in Q1 2023 and 3 closed out, a net change of -2 holders.
- The largest Protara Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $193K added.
- The largest Protara Therapeutics seller in Q1 2023 was OrbiMed, an estimated $123K sold.
Based on aggregated 13F filings for Q1 2023.